<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626469</url>
  </required_header>
  <id_info>
    <org_study_id>2011P002805</org_study_id>
    <nct_id>NCT01626469</nct_id>
  </id_info>
  <brief_title>Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients</brief_title>
  <official_title>Eye Blood Flow and the Kidney</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to the determine the effect of salt intake and Captopril on the
      ophthalmic artery (OA) blood supply of individuals with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this study is to ascertain if salt intake affects ophthalmic artery
      (OA) blood flow. In addition, we will study both the eye and kidney response to ACE
      inhibition compared to placebo while controlling salt intake in subjects with Type 2 diabetes
      mellitus.

      We hypothesize that salt intake will affect OA blood flow.

      We will initially look at both eye and renal response to subjects on a low salt diet (10mEq
      Na/day) followed by response to high salt diet (200mEq Na/day). In addition, we may look at
      eye response while subjects consume their regular diet.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ophthalmic artery blood flow from baseline</measure>
    <time_frame>1 hour post drug, 2 hours post drug, 3 hours post drug</time_frame>
    <description>Eye blood flow will be measured at baseline and post drug time points (3 total)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure from baseline</measure>
    <time_frame>Every 15 minutes for 3 hours</time_frame>
    <description>Blood pressure will be monitored throughout the study starting at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal plasma flow (RPF) from baseline</measure>
    <time_frame>1 hour post drug, 2 hours post drug, 3 hours post drug</time_frame>
    <description>Renal Plasma Flow (to measure kidney function) will be measured at baseline and post drug time points (3 total)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Captopril</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Captopril</intervention_name>
    <description>25mg Captopril</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Captopril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Captopril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus

          -  Heart Attack or Stroke within the last 6 months

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman K Hollenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ebrahim Barkoudah, M.D.,M.P.H.</last_name>
    <role>Study Director</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Norman K. Hollenberg, MD, PhD</investigator_full_name>
    <investigator_title>Director of Physiologic Research Division, Department of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

